Kintor Pharmaceutical has reported encouraging results from the investigator initiated clinical trial of Proxalutamide for treating female Covid-19 patients.

In November, the trial initiated the enrolment of 168 female patients after obtaining promising results from male patients.

Patients were randomised in a 2:1 ratio and given either Proxalutamide plus standard care (Proxalutamide group) or placebo plus standard care (control group).

The number of participants hospitalised with Covid-19 and the ‘COVID-19 Ordinal Outcome Scale’ in 30 days formed the trial’s primary endpoints.

‘COVID-19 Ordinal Outcome Scale’ is an eight-point ordinal scale used by the US National Institute of Allergy and Infection Diseases, like mechanical ventilation usage and death.

Interim analysis conducted on 7 January is based on 60 patients in the Proxalutamide arm and 35 patients in the control arm.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

According to the latest data from the trial, the percentage of hospitalisation, ICU admission, and the need for mechanical ventilation and death was at 1.7% versus 17.1%, 0% versus 8.6%, 0% versus 5.7% and 0% versus 2.9% in the Proxalutamide and placebo cohorts, respectively.

Kintor Pharmaceutical noted that the trial is anticipated to complete enrolment in February and conclude data collection by March.

Kintor Pharmaceutical founder, chairman and CEO Dr Tong Youzhi said: “Special thanks to the AndroCo group led by Dr Andy Goren, Dr Flávio Adsuara Cadegiani, Dr John McCoy and Dr Carlos Gustavo Wambier, who are conducting this important investigator-initiated study.

“Although the female group has lower androgen level as compared to the male group, the data showed that Proxalutamide could significantly ameliorate symptoms and prevent hospitalisation for Covid-19 female patients, which paves the way for our Phase III MRCT registrational trial in the near future.”